AsemconnectVietnam - According to documents submitted to the 2026 Annual General Meeting of Shareholders, OPC Pharmaceutical Joint Stock Company (HOSE: OPC) plans consolidated revenue of VND1,250 billion and consolidated pre-tax profit of VND175 billion for 2026, an increase of 11.2% and 18.2% respectively compared to 2025.

At the parent company, the revenue target is VND1,150 billion and pre-tax profit is VND165 billion, an increase of 10% and 18.3% respectively.
The Board of Directors is submitting to the General Meeting for approval the 2025 dividend plan with a total rate of 25% of par value, including 8% in cash, equivalent to VND51.24 billion, and 17% in shares, equivalent to VND108.89 billion. After issuing an additional 10,888,651 shares to pay dividends, OPC's charter capital will increase from VND640.5 billion to VND749.4 billion. The profit distribution plan for 2026 anticipates a minimum dividend rate of 12% of charter capital.
Regarding the industry outlook, OPC's management board predicts that the Vietnamese pharmaceutical market will maintain an average growth rate of approximately 8% in the 2023-2025 period, with sales reaching USD 9 billion, reflecting a shift towards higher-value products. During the period 2026-2030, the Vietnamese pharmaceutical industry is assessed as a market with positive growth potential, but faces systemic risks such as dependence on imported raw materials from China and India, and pressure from exchange rates and high domestic interest rates.
OPC anticipates that differentiation within the industry will become increasingly clear, as new regulations on bidding and production standards continue to favor businesses with strong financial capabilities, meeting EU-GMP standards and possessing a portfolio of specialized and high-value-added drugs; while those focusing on general-purpose drugs face greater competitive pressure.
In this context, OPC is positioning itself to shift from a traditional pharmaceutical manufacturing enterprise to a research-production model for medicinal herbs based on scientific foundations and a closed-loop medicinal herb value chain. The company is currently ranked 7th in the Top 10 reputable pharmaceutical companies in Vietnam in 2025, an improvement from its 8th position the previous year. Key tasks for 2026 include increasing investment in research and development of high-value medicinal products, and expanding the medicinal product value chain towards commercialization.
In 2025, OPC recorded consolidated revenue of VND1,124.55 billion, a 16% increase compared to 2024, although it did not meet the target of VND1,240 billion. Consolidated pre-tax profit reached VND148.04 billion, an 8% increase compared to 2024, completing 83.6% of the annual plan.
At the parent company, revenue reached VND1,045.63 billion, a 17.8% increase, and pre-tax profit reached VND139.42 billion, a 12.4% increase. The management board estimates this growth rate to be about 5 percentage points higher than the overall growth rate of the pharmaceutical industry.
N.Nga
Source: VITIC/Tinnhanhchungkhoan